Table 2 Summary of characteristics of the public microarray datasets compared with IST patients
Dataset (year) | Patient number | Age median (min-max) | Stage I-II-III | NSCLS subtype | 5-years cumulative survival (95% CI) | Microarray platform |
|---|---|---|---|---|---|---|
IST (2012) | 82 | 69 (47–82) | 44-15-23 | ADK SCC other | 0.54 (.44-.66) | RQ-PCR |
[24] Shedden et al. (2008) all patients | 442 | 65 (33–87) | 276-96-69 | ADK | 0.55 (.50-.60) | Affymetrix U133a |
[24] Shedden et al. (2008) adjuvant-naïve | 330 | 65 (33–87) | 230-60-40 | ADK | 0.60 (.55-.66) | Affyimetrix U133a |
[25] Lee et al. (2008) | 138 | 62 (13–82) | n.a. | ADK SCC | 0.50 (.42-.59) | Affymetrix U133plus2 |
[26] Tomida et al. (2009) | 117 | 61 (32–84) | 79-13-25 | ADK | 0.66 (.58-.75) | Agilent 44k |
[27] Roepman et al. (2009) | 172 | 54 (22–79) | 117-55-0 | ADK SCC other | 0.65 (.57-.74) | Agilent 44k* |
[28] Okayama et al. (2012) | 226 | 61 (30–76) | 168-58-0 | ADK | 0.84 (.79-.89) | Affymetrix U133plus2 |
[29] Botling at al. (2013) | 196 | 65 (39–84) | 130-35-31 | ADK SCC | 0.42 (.35-.49) | Affymetrix U133plus2 |